Press Release: Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney

Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney NEW YORK, June 14, 2007 -- Bristol-Myers Squibb today acknowledged the statement by the Hon. Christopher J. Christie, the U.S. Attorney for the District of New Jersey, regarding tomorrow's expiration of the deferred prosecution agreement (DPA). During the past two years, Bristol-Myers Squibb has complied with the letter and spirit of the DPA and has made significant enhancements to its compliance structures and practices. The company believes its business operations are stronger today as a result of having embraced a culture of compliance. The expiration of the DPA will not diminish the company's commitment to exemplary corporate citizenship, effective corporate governance practices and the highest principles of integrity and professionalism. Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. CONTACT: Media, Laura Hortas, Communications, +1-609-252-4587,, or Tony Plohoros, Communications, +1-609-252-7938,, both of Bristol-Myers Squibb [email protected] [email protected]

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.